Dr. Smith's ECG Blog
APRIL 18, 2024
Written by Jesse McLaren A 70 year old with prior MIs and stents to LAD and RCA presented to the emergency department with 2 weeks of increasing exertional chest pain radiating to the left arm, associated with nausea. The pain recurred at rest 90 minutes prior to presentation, felt like the patient’s prior MIs, and was not relieved by 6 sprays of nitro.
Med Page Today
APRIL 18, 2024
(MedPage Today) -- Tirzepatide (Zepbound) injections reduced sleep apnea severity among patients with obesity, regardless of positive airway pressure (PAP) use, according to topline data from two phase III trials. In the SURMOUNT-OSA 1 study.
DAIC
APRIL 18, 2024
Based on continuous monitoring of early recurrence of atrial tachyarrhythmia immediately after patients have undergone atrial fibrillation ablation, Musat et al. recommend shortening the blanking period from three months to one. Graphic courtesy of Dan Musat milla1cf Thu, 04/18/2024 - 13:32 April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period immediately after atrial fibrillation (AF) ablation, when early occurrences of AF are thought not
HCPLive
APRIL 18, 2024
Modern large language models perform strongly on ophthalmic knowledge assessments and approach or exceed the scores of fully qualified and trainee ophthalmologists.
DAIC
APRIL 18, 2024
Getty Images milla1cf Thu, 04/18/2024 - 13:20 April 18, 2024 — Bayer AG and Asklepios BioPharmaceutical , Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for the AB-1002 program. AB-1002 is an investigational one-time gene therapy that is administered to the heart with the intention of helping to promote the production of a constitutively active
HCPLive
APRIL 18, 2024
Almost 50% of fibromyalgia patients use cannabis for symptom relief, according to new study. Experts suggest results underline need for clinician awareness, further research.
DAIC
APRIL 18, 2024
milla1cf Thu, 04/18/2024 - 13:23 April 18, 2024 — Karoo Health , the only operational provider of cardiac value-based care (VBC) enablement with published results, today launched Kohere.ai, its proprietary cloud-based platform that augments the company's proven model of care (MoC) for cardiovascular healthcare providers, payers, and patients. The Kohere.ai platform launch and 2024 roadmap are composed of the following modules: FLOW is uniquely designed and A/B tested to drive Karoo Health's MoC
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
Science Daily - Heart Disease
APRIL 18, 2024
A heart attack will leave a permanent scar on a human heart, yet other animals, including zebrafish, can clear cardiac scar tissue and regrow damaged muscle as adults. Biologists sheds new light on how zebrafish heal heart tissue by comparing how this species responds to heart injury with medaka, a fish species that cannot regenerate cardiac tissue.
HCPLive
APRIL 18, 2024
Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.
Circulation
APRIL 18, 2024
Circulation, Ahead of Print. Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous inflammation of the myocardium and may present with high-grade conduction disease, ventricular arrhythmias, and right or left ventricular dysfunction. Over the past several decades, the prevalence of cardiac sarcoidosis has increased. Definitive histological confirmation is often not possible, so clinicians frequently face uncertainty about the accuracy of diagnosis.
HCPLive
APRIL 18, 2024
New phase 3 findings show daily oral budesonide reduces eGFR decline while maintaining patient quality of life over 2 years.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
BackgroundPostoperative acute kidney injury (PO-AKI) is a prevalent complication among patients with acute type A aortic dissection (aTAAD) for which unrecognized trajectories of renal function recovery, and their heterogeneity, may underpin poor success in identifying effective therapies.MethodsThis was a retrospective, single-center cohort study in a regional Great Vessel Center including patients undergoing aortic dissection surgery.
HCPLive
APRIL 18, 2024
Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
BackgroundAtrial fibrillation (AF) is a common cardiac arrhythmia that is associated with obesity and obstructive sleep apnea syndrome (OSA). Obesity and OSA may increase the risk of AF by affecting cardiovascular health.MethodsThe study used the Mendelian randomization (MR) approach, combined with two-sample and multivariable analyses, to assess the relationships between obesity, OSA, and AF.
HCPLive
APRIL 18, 2024
Experts discuss the management of dry eye in the presence of concurrent ocular conditions, as well as managing dry eye before undergoing cataract and refractive surgery.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
Inflammation and dyslipidemia are critical inducing factors of atherosclerosis. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors and control the expression of multiple genes that are involved in lipid metabolism and inflammatory responses. However, synthesized PPAR agonists exhibit contrary therapeutic effects and various side effects in atherosclerosis therapy.
HCPLive
APRIL 18, 2024
Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
Cardiovascular magnetic resonance (CMR) imaging has become an invaluable clinical and research tool. Starting from the discovery of nuclear magnetic resonance, this article provides a brief overview of the key developments that have led to CMR as it is today, and how it became the modality of choice for large-scale population studies.
HCPLive
APRIL 18, 2024
A propensity score-matched, new-user analysis suggests SGLT2 inhibitors may reduce gout risk in type 2 diabetes patients relative to other second-line therapies.
Nature Reviews - Cardiology
APRIL 18, 2024
Nature Reviews Cardiology, Published online: 19 April 2024; doi:10.1038/s41569-024-01027-9 In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.
HCPLive
APRIL 18, 2024
A recent study found Black individuals had a sharp increase in midlife deaths from suicide, drug overdose, and alcoholic liver disease after 2015.
Frontiers in Cardiovascular Medicine
APRIL 18, 2024
Cardiovascular diseases pose a major threat to human life, functional activity, and quality of life. Once the disease is present, patients can experience varying degrees of problems or limitations on three levels: physical, psychological, and social. Patients with cardiovascular disease are always at risk for adverse cardiac events, decreased physical activity, psychoemotional disturbances, and limited social participation due to their varying pathologies.
HCPLive
APRIL 18, 2024
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
The American Journal of Cardiology
APRIL 18, 2024
Publication date: Available online 17 April 2024 Source: The American Journal of Cardiology Author(s): Thomas Modine, John K. Forrest, Nicolas M. Van Mieghem, G. Michael Deeb, Steven J. Yakubov, Walid Ben Ali, Didier Tchétché, Ka Yan Lam, Jae K. Oh, Jian Huang, Roxana Mehran, Michael J.
HCPLive
APRIL 18, 2024
Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.
The American Journal of Cardiology
APRIL 18, 2024
Publication date: Available online 17 April 2024 Source: The American Journal of Cardiology Author(s): Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, Karen Chiswell, Zachary Lampron, Christina Shay, Keith Marsolo, W. Schuyler Jones, Javed Butler, Raj C. Shah, Alanna M. Chamberlain, Daniel E. Ford, Howard S. Gordon, Wenke Hwang, Alexander Chang, Ajaykumar Rao, Hayden B.
HCPLive
APRIL 18, 2024
A new study found an intervention targeting proton pump inhibitor overuse was linked to an absolute reduction of 7.3%.
Dr. S. Venkatesan MD
APRIL 18, 2024
Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heart disease, whether it is valvular or myocardial disease. It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity. Drugs like inotropes, pre-load , afterload modulators like diuretics and vasodilators can take care to a certain extent.
The American Journal of Cardiology
APRIL 18, 2024
Publication date: Available online 18 April 2024 Source: The American Journal of Cardiology Author(s): Suzanne J. Baron, C. Michael Gibson, Ripal T.
NEJM Journal Watch - Cardiology
APRIL 18, 2024
At 1 year, clinical outcomes were similar and supraannular valve recipients had a significantly lower risk of bioprosthetic-valve dysfunction.
NEJM Journal Watch - Cardiology
APRIL 18, 2024
A dedicated device for AR demonstrated safety and efficacy that was noninferior to performance goals.
Expert insights. Personalized for you.
117 
Let's personalize your content